08/03/22 3:01 AMNasdaq : MYNZ managementlow floatMainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of DevelopmentMainz Biomed N.V. (NASDAQ:MYNZ) (“MainzRHEA-AIvery positive
07/19/22 3:01 AMNasdaq : MYNZ managementlow floatMainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory BoardRenowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer Diagnostics Dr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos College of Physicians and Surgeons and serves as Co-leader of the Tumor Biology andRHEA-AIvery positive
07/12/22 3:01 AMNasdaq : MYNZ low floatMainz Biomed Today to Provide Corporate Update for First Half of 2022Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, will host aRHEA-AIneutral
07/05/22 3:01 AMNasdaq : MYNZ low floatMainz Biomed Provides Corporate Update for First Half of 2022Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to host aRHEA-AIvery positive
06/28/22 3:01 AMNasdaq : MYNZ low floatMainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlertMainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic companyRHEA-AIneutral
06/14/22 3:01 AMNasdaq : MYNZ managementclinical triallow floatMainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA SubmissionJane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices Will manage the design and logistical operations of Mainz Biomed’s clinical trials in the US and Europe to support FDA submission BERKELEY,RHEA-AIvery positive
06/01/22 3:01 AMNasdaq : MYNZ low floatMainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory ComplianceMainz Biomed N.V. (NASDAQ:MYNZ) (“MainzRHEA-AIneutral
05/19/22 3:01 AMNasdaq : MYNZ partnershiplow floatMainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” orRHEA-AIvery positive
05/17/22 3:01 AMNasdaq : MYNZ conferenceslow floatMainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring ConferenceMainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participatingRHEA-AIneutral
05/09/22 8:01 AMNasdaq : MYNZ conferenceslow floatMainz Biomed to Host Key Opinion Leader Event at DDW 2022Mainz Biomed N.V. (NASDAQ:MYNZ)RHEA-AIneutral